Park Ha Biological (BYAH) Fundamental Analysis: Revenue, Earnings & Valuation

1.65 / 10

Underperform

Fundamental rating is Underperform with a 1.6/10 score. Key issues include a negative net profit margin, ROE of –609.9%, and a high current‑liabilities‑to‑total‑liabilities ratio (96%). Operating cycle and cash‑flow ratios are modest, reinforcing a selective investment view.

Analysis Checks(5/7)

Shareholders’ equity attributable to parent company / Total liabilities (%)

Value2.04

Score3/3

Weight-16.56%

1M Return2.25%

Operating cycle

Value227.10

Score2/3

Weight24.16%

1M Return-3.94%

Net cash flow from operating activities / Operating revenue (%)

Value3.40

Score2/3

Weight14.74%

1M Return-2.30%

Current liabilities / Total liabilities (%)

Value96.12

Score0/3

Weight34.96%

1M Return-8.17%

Net profit margin (%)

Value-965.00

Score2/3

Weight13.93%

1M Return-2.22%

ROE (diluted) (%)

Value-609.90

Score1/3

Weight14.84%

1M Return-2.63%

Net profit / Total operating revenue (%)

Value-965.00

Score2/3

Weight13.93%

1M Return-2.22%

Is BYAH fundamentally strong?

BYAH scores 1.65/10 on fundamentals and holds a Premium valuation at present. Backed by its -885.84% ROE, -965.00% net margin, -0.14 P/E ratio, 0.84 P/B ratio, and -4410.42% earnings growth, these metrics solidify its Underperform investment rating.